Loading...

HEPION PHARMACEUTICALS INC Management Changes 8-K Filing

HPN

HEPION PHARMACEUTICALS INC

()

2025 8-K

Management Change

License Agreement

Management Change

Asset Acquisitions

Forced Delisting

Asset Acquisitions

Balance Sheet Update

Equity Financing

Financial Update

Clinical Trial Update

Nasdaq Compliance Notice

Management Changes

Merger Agreement

Appointment of Director

Management Changes

Registered Direct Offering ...

Resignation of Director

Dismissal of BDO USA, P.C. ...

Resignation of CEO and Rest...

Securities Purchase Agreement

Investor Meetings

Equity Offerings

Annual Meeting of Stockholders

Regulation FD Disclosure, O...

Reverse Stock Split

External Links:

Hepion Pharmaceuticals, Inc. appointed Dr. Kaouthar Lbiati as interim CEO effective June 16, 2025, with a base salary of $350,000 and a potential performance bonus of 35% based on targets. This event was reported on June 3, 2025.

AI Assistant

HEPION PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.